PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. PATIENTS AND METHODS: Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m(2) plus melphalan 180 mg/m(2). RESULTS: Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. CONCLUSION: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors. (c) 2008 Wiley-Liss, Inc.
PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. PATIENTS AND METHODS: Subjects were in second remission or had minimal residual disease at the time of study entry. The conditioning regimen consisted of cyclophosphamide 6,000 mg/m(2) plus melphalan 180 mg/m(2). RESULTS: Twenty-nine evaluable pediatric patients were accrued. The most frequent major toxicities were myelosuppression, infections, and stomatitis, but no toxic deaths were recorded. Best responses were: CR = 6, CCR = 13, PR = 6, SD = 2, and PD = 2. There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10). Two germinoma survivors received radiotherapy after autografting for presumptive progressive disease. CONCLUSION: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors. (c) 2008 Wiley-Liss, Inc.
Authors: Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: C A Hurwitz; L C Strauss; J Kepner; C Kretschmar; M B Harris; H Friedman; L Kun; R Kadota Journal: J Pediatr Hematol Oncol Date: 2001 Jun-Jul Impact factor: 1.289
Authors: R P Kadota; C F Stewart; M Horn; J F Kuttesch; P C Burger; J L Kepner; L E Kun; H S Friedman; R L Heideman Journal: J Neurooncol Date: 1999-05 Impact factor: 4.130
Authors: M L Graham; J E Herndon; J R Casey; S Chaffee; G H Ciocci; J P Krischer; J Kurtzberg; M J Laughlin; D C Longee; J F Olson; N Paleologus; C N Pennington; H S Friedman Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: ZoAnn E Dreyer; Richard P Kadota; Clinton F Stewart; Henry S Friedman; Donald H Mahoney; Larry E Kun; Charles W McCluggage; Peter C Burger; James Kepner; Richard L Heideman Journal: Neuro Oncol Date: 2003-10 Impact factor: 12.300
Authors: Lisa R Bomgaars; Mark Bernstein; Mark Krailo; Richard Kadota; Soma Das; Zhengjia Chen; Peter C Adamson; Susan M Blaney Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544
Authors: D H Mahoney; D Strother; B Camitta; T Bowen; T Ghim; T Pick; D Wall; L Yu; J J Shuster; H Friedman Journal: J Clin Oncol Date: 1996-02 Impact factor: 44.544
Authors: E Bouffet; M C Baranzelli; C Patte; M Portas; C Edan; P Chastagner; F Mechinaud-Lacroix; C Kalifa Journal: Br J Cancer Date: 1999-03 Impact factor: 7.640
Authors: Ira J Dunkel; Sharon L Gardner; James H Garvin; Stewart Goldman; Weiji Shi; Jonathan L Finlay Journal: Neuro Oncol Date: 2010-01-11 Impact factor: 12.300
Authors: Eduard H Panosyan; Alan K Ikeda; Vivian Y Chang; Dan R Laks; Charles L Reeb; La Vette Bowles; Joseph L Lasky; Theodore B Moore Journal: J Transplant Date: 2011-04-14
Authors: Hee Jo Baek; Hyeon Jin Park; Ki Woong Sung; Soo Hyun Lee; Jung Woo Han; Kyung Nam Koh; Ho Joon Im; Hyoung Jin Kang; Kyung Duk Park Journal: J Neurooncol Date: 2013-07-04 Impact factor: 4.130
Authors: Francisco Bautista; Victoria Fioravantti; Teresa de Rojas; Fernando Carceller; Luis Madero; Alvaro Lassaletta; Lucas Moreno Journal: Cancer Med Date: 2017-10-04 Impact factor: 4.452